{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Steffens EB"],"funding":["NCI NIH HHS"],"pagination":["e238-e247"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9970276"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(2)"],"pubmed_abstract":["<h4>Purpose</h4>More than half of individuals with serious mental illness (SMI) smoke, contributing to premature cancer mortality. A cancer diagnosis provides an opportunity to assist with smoking cessation; however, supportive oncology trials frequently exclude patients with SMI. To fill this gap, we examined differences in engagement and tobacco cessation in a pragmatic clinical trial.<h4>Methods</h4>We recruited 303 participants from two National Cancer Institute-designated Comprehensive Cancer Centers, of which 10% had prior diagnoses of SMI (major depressive disorder, bipolar disorder, and schizophrenia spectrum disorders). We compared self-reported smoking behaviors, patient attitudes and beliefs about cessation, and rates of trial completion, engagement, and smoking abstinence among"],"journal":["JCO oncology practice"],"pubmed_title":["Patients With Serious Mental Illness Can Engage in Tobacco Treatment Trials and Tobacco Cessation Interventions During Cancer Treatment."],"pmcid":["PMC9970276"],"funding_grant_id":["K24 CA197382","P30 CA008748","R01 CA166147","K08 CA230185"],"pubmed_authors":["Ostroff JS","Rigotti NA","Irwin KE","Perez GK","Park ER","Rasmussen AW","Regan S","Ponzani C","Steffens EB","Streck JM","Muzikansky A"],"additional_accession":[]},"is_claimable":false,"name":"Patients With Serious Mental Illness Can Engage in Tobacco Treatment Trials and Tobacco Cessation Interventions During Cancer Treatment.","description":"<h4>Purpose</h4>More than half of individuals with serious mental illness (SMI) smoke, contributing to premature cancer mortality. A cancer diagnosis provides an opportunity to assist with smoking cessation; however, supportive oncology trials frequently exclude patients with SMI. To fill this gap, we examined differences in engagement and tobacco cessation in a pragmatic clinical trial.<h4>Methods</h4>We recruited 303 participants from two National Cancer Institute-designated Comprehensive Cancer Centers, of which 10% had prior diagnoses of SMI (major depressive disorder, bipolar disorder, and schizophrenia spectrum disorders). We compared self-reported smoking behaviors, patient attitudes and beliefs about cessation, and rates of trial completion, engagement, and smoking abstinence among","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-26T11:57:01.727Z","creation":"2025-02-19T04:59:54.262Z"},"accession":"S-EPMC9970276","cross_references":{"pubmed":["36351206"],"doi":["10.1200/op.22.00505","10.1200/OP.22.00505"]}}